Compare Prospect Capital Corporation (PSEC) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prospect Capital Corporation vs Revvity Inc — how do they compare? Prospect Capital Corporation trades at $1.72 (market cap $974.22M), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 17.4× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (23.01%). Which is the better fit depends on your goals — on Pluang, investors hold Prospect Capital Corporation for 78 Days and Revvity Inc for 12 Days on average.
| PSEC | RVTY | |
|---|---|---|
Market Cap | $974.22M | $16.98B |
Volume | 5,779,996 | 1,456,900 |
Sector | Financials | Health |
52-Week High | $3.05 | $157.36 |
52-Week Low | $1.72 | $82.26 |
Typical Hold Time | 78 Days | 12 Days |
Enterprise Value | $2.73B | $19.30B |
Dividend Yield | 23.01% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSEC trades at $1.82, down 1.09% on the day, with a bearish technical signal from moving averages. The company reported negative revenue and net income for 2025, though it has beaten EPS estimates in recent quarters. Recent news highlights dividend declarations and management commentary on the firm's track record.
The outlook is clouded by financial volatility and a mixed analyst consensus. The primary opportunity is the high dividend yield, but risks include persistent negative profitability, portfolio contraction, and a majority of analysts rating the stock as Hold or Sell.
RVTY trades at $152.16, down 0.94% today, near its recent 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for three consecutive quarters. Recent positive developments include a Zacks upgrade to Buy (2026-10-02) and the launch of a new Type 1 diabetes screening kit in Europe (Business Wire, 2026-09-24).
The outlook is positive, supported by earnings momentum and strategic expansions, but the stock's premium valuation (P/E of 73.15) and margin pressures pose risks. Analyst consensus is bullish with a $132.13 price target, though the current price exceeds it, suggesting near-term consolidation may occur before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
